What is M3 Wake Research?
M3 Wake Research operates as a premier network of integrated investigational sites, providing essential infrastructure for the biopharmaceutical, biotechnology, and medical device sectors. With a footprint spanning 23 fully equipped sites, the company specializes in the execution of Phase I-IV clinical trials across a diverse range of therapeutic indications. The organization distinguishes itself through a proprietary model that combines rapid trial start-up, strategic volunteer recruitment, and high-retention subject management. By utilizing standardized operating procedures and centralized marketing, M3 Wake Research has successfully facilitated over 9,100 research studies, positioning itself as a critical partner for sponsors and contract research organizations (CROs) seeking to navigate the complexities of modern drug development and medical innovation.
How much funding has M3 Wake Research raised?
M3 Wake Research has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in M3 Wake Research
PPP
Public-Private Partnership
What's next for M3 Wake Research?
With this major strategic investment, M3 Wake Research is poised to scale its clinical trial capabilities and enhance its service delivery model. The firm is expected to focus on expanding its site network and integrating advanced digital recruitment technologies to further reduce trial timelines. As the demand for high-quality, rapid-enrollment clinical research continues to rise, M3 Wake Research is well-positioned to capitalize on its established reputation for excellence. Future growth initiatives will likely prioritize the adoption of decentralized trial methodologies and the expansion of its therapeutic expertise, ensuring the company remains at the forefront of the global clinical research ecosystem while delivering exceptional value to its stakeholders and the patients who rely on the development of novel medical therapies.
See full M3 Wake Research company page
